You are here

Biological Decontamination for Forward-Deployed Airbase Using Low Temperature Air Plasmas

Award Information
Agency: Department of Defense
Branch: Air Force
Contract: F49620-02-C-0052
Agency Tracking Number: F023-0084
Amount: $99,333.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
980 American Pacific Drive, Suite 111
Henderson, NV 89014
United States
DUNS: 001200299
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Theodore Anderson
 Researcher
 (702) 734-1888
 AnderDrTed@aol.com
Business Contact
 Jerry Polis
Title: President
Phone: (702) 734-1888
Email: jerrypolis@aol.com
Research Institution
 Eastern Virginia Medical School
 Stephen Beebe, Phd
 
Department of Pediatrics, 855 W. Brambleton Ave.
Norfolk, VA 23510
United States

 (757) 668-6465
 Nonprofit College or University
Abstract

"ASI's plasma consultant, Igor Alexeff, PhD, has invented, tested and patented an atmospheric pressure, dc of 60 Hz AC discharge, that has been operated in air, helium, argon and nitrogen. The apparatus has in laboratory testing successfully destroyedmicroorganisms. The apparatus does not require a complicated, fragile RF power supply for operation. We propose it to be developed into equipment for decontamination of bioterror materials in the field. The device works well with a simple 60 Hz. Neontransformer. The electrodes are made of unglazed ceramic. The ion density has been measured to be 10 exp 12 per cc. Power consumption used was 300 watts to create several liters of helium plasma. In order to carry out the proposed Air Force program ofidentifying and evaluating the biologically active species present in the discharge, we propose employing new sensors that can unambiguously detect and measure the concentration of O2, NO and NO2, ultraviolet light, charged ions, and metastable atoms. Inaddition, we will evaluate methods of producing each species separately. The isolation of each species will be used in the biological studies planned in Phase II to identify which species is effective in biological decontamination. The methodology andapparatus proposed by ASI could revolutionize sterilization techniques throughout the civilian and military communities, if successfully commercialized. The commercial market for safer atmospheric plasma decontamination is quite large. Sepsis is the majorpost-operative cause of death in American hospitals. "

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government